Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076)
Open Access
- 17 June 2020
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 10 (6), 919
- https://doi.org/10.3390/biom10060919
Abstract
Although bevacizumab (Avastin®) has been approved as an antiangiogenic agent against some cancers, the efficacy is transient and unsatisfactory in other cancers most likely owing to the presence of alternative proangiogenic factors. Therefore, simultaneous blocking of several proangiogenic factors may be a promising strategy for antiangiogenic cancer therapeutics. Accordingly, neuropilin-1 (NRP1) is an attractive target because it serves as a multifunctional receptor for the vascular endothelial growth factor (VEGF) family. Here, we aimed to generate and test an anti-VEGFA and anti-NRP1 dual-targeting bispecific antibody (named as IDB0076) by genetic fusion of an NRP1-targeting peptide to the C-terminus of the bevacizumab heavy chain. Similar to the parental antibody (bevacizumab), IDB0076 suppressed VEGFA-induced migration of human endothelial cells. In contrast, IDB0076 inhibited endothelial-cell migration induced by other angiogenesis growth factors and manifested a more potent antitumor activity than that of bevacizumab in a murine tumor xenograft model. When toxicity was preliminarily evaluated in cynomolgus monkeys, IDB0076 showed no substantial adverse effects, e.g., the absence of noticeable nephrotoxicity, which has previously been documented for the combination therapy of bevacizumab and an anti-NRP1 antibody. Thus, VEGFA-and-NRP1 dual-targeting bispecific antibody IDB0076 may be a potent and safe anticancer agent worthy of further preclinical and clinical studies.Keywords
Funding Information
- National Research Foundation of Korea (2015M3A9D9074304)
This publication has 40 references indexed in Scilit:
- Neuropilin-1 Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor MicroenvironmentCancer Research, 2012
- Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical ExperienceClinical Cancer Research, 2012
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis, 2012
- Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migrationBritish Journal of Cancer, 2011
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Journal of Clinical Oncology, 2007
- Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodiesProceedings of the National Academy of Sciences of the United States of America, 2007
- Function Blocking Antibodies to Neuropilin-1 Generated from a Designed Human Synthetic Antibody Phage LibraryJournal of Molecular Biology, 2007
- Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor GrowthCancer Cell, 2007
- Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal AntibodyToxicologic Pathology, 1999
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971